Fig. 1From: Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population a REALISTIC trial design. b Subject disposition. aDB phase. bOne week 12 CZP completer discontinued after week 12 due to an AE, did not receive any study medication in the OL phase, and was not included in the OL analysis set. AE adverse event, CZP certolizumab pegol, DMARD disease-modifying antirheumatic drug, OLE open-label extension, Q2W every other weekBack to article page